摘要
肥胖及其相关代谢异常是危害人类健康的重要问题,对人们的生活质量有着深远影响。越来越多的证据表明,肥胖相关代谢异常与遗传、慢性低度炎症和肠道菌群特异性改变等多因素相关。随着人们对肥胖及其相关疾病的不断重视和深入研究,肥胖相关新型标志物和肠道菌群等将有助于肥胖及其相关代谢异常的精确诊断和风险预测。饮食、身体活动或体育锻炼等生活方式的改变是肥胖及其相关代谢异常治疗的基础,药物治疗和减重手术正变得越来越重要,对肠道菌群及其代谢物的多组学分析也为肥胖及其相关代谢异常提供了新的治疗靶点。文章着重讨论肥胖相关代谢异常在诊断和治疗方面的新进展。
Obesity and its related metabolic abnormalities are important problems that endanger human health and have a profound impact on the quality of life.There is increasing evidence that obesity-related metabolic abnormalities are associated with multiple factors,including genetics,chronic low-grade inflammation,and specific changes in gut microbiota.With the increasing attention and researches on obesity and its related metabolic diseases,new obesity-related biomarkers and gut microbiota will contribute to the accurate diagnosis and risk prediction of obesity and its related metabolic abnormalities.Lifestyle interventions such as diet,physical exercise are the basis for the treatment of obesity and its related metabolic abnormalities.Drug therapy and bariatric surgery are becoming more and more important.Multi-omics analysis of gut microbiota and its metabolites also provides new therapeutic methods for obesity and its related metabolic abnormalities.This article focuses on the recent advances in the diagnosis and treatment of obesity-related metabolic abnormalities.
作者
李华婷
贾伟平
LI Hua-ting;JIA Wei-ping(Department of Endocrinology and Metabolism,the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University,Shanghai 200233,China)
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2022年第2期89-95,共7页
Chinese Journal of Practical Internal Medicine
基金
上海市临床重点专科建设“振龙头”项目。
关键词
肥胖相关代谢异常
生物标志物
治疗靶点
肥胖
obesity-related metabolic abnormalities
biomarkers
therapeutic target
obesity
